The National Institute for Health and Care Excellence (NICE) has approved the routine use of two pharmacological interventions for the treatment of spinal muscular atrophy (SMA) within the English healthcare system.

國家健康與照護卓越研究院 (NICE) 已批准在英國醫療體系中，常規使用兩種藥物干預措施來治療脊髓性肌肉萎縮症 (SMA)。

The transition of nusinersen, an injectable agent, and risdiplam, an oral medication, from a restricted special access framework to general NHS implementation follows a period of evidence accumulation regarding their efficacy. These disease-modifying therapies are intended to mitigate the progression of SMA, a rare genetic pathology typically precipitated by mutations in the SMN1 gene on chromosome 5. The condition is characterized by the degeneration of motor neurons, which disrupts the transmission of electrical impulses from the cerebral cortex to the muscular system, resulting in progressive atrophy and muscle weakness.

注射藥劑 nusinersen 與口服藥物 risdiplam 從受限的特殊獲取框架轉為 NHS 全面實施，是基於一段時間內關於其療效的證據累積。這些改變疾病進程的療法旨在減緩 SMA 的惡化，SMA 是一種罕見的遺傳疾病，通常由 5 號染色體上的 SMN1 基因突變引起。此病症的特徵是運動神經元退化，導致從大腦皮質到肌肉系統的電衝擊傳導中斷，進而導致漸進性萎縮和肌肉無力。

Clinical manifestations of SMA Type 1, the most acute variant, typically emerge within the first six months of life. Dr. Charlotte Roy of Muscular Dystrophy UK identifies critical diagnostic indicators, including hypotonia (low muscle tone), impaired bulbar functions affecting swallowing and respiration, and the inability to achieve developmental milestones such as unsupported sitting or cranial elevation. In the absence of therapeutic intervention, Muscular Dystrophy UK estimates a life expectancy of less than two years for Type 1 patients. However, NHS England reports that these interventions have already facilitated the survival of 73 children to age five or beyond.

SMA 1 型是最急性亞型，臨床表現通常在出生後六個月內出現。英國肌肉萎縮症協會 (Muscular Dystrophy UK) 的 Charlotte Roy 醫師指出關鍵的診斷指標，包括肌張力低下 (hypotonia)、影響吞嚥與呼吸的球部功能障礙，以及無法達到發育里程碑（如無支撐坐立或抬頭）。在缺乏治療干預的情況下，英國肌肉萎縮症協會估計 1 型患者的預期壽命不足兩年。然而，英格蘭 NHS 報告指出，這些干預措施已幫助 73 名兒童生存至五歲或以上。

Parallel to these clinical advancements, there is an institutional movement toward systemic early detection. A study involving approximately 750,000 newborns in England is currently assessing the feasibility of integrating SMA screening into standard neonatal protocols. This initiative has been supported by public advocacy from Jesy Nelson following the diagnosis of her children. The necessity of early detection is underscored by the irreversible nature of motor neuron loss, whereby prompt pharmacological intervention is required to optimize patient outcomes.

與這些臨床進展平行的是，機構正推動系統性的早期檢測。一項涉及英格蘭約 75 萬名新生兒的研究目前正在評估將 SMA 篩檢整合至標準新生兒方案的可行性。在 Jesy Nelson 的孩子確診後，她公開倡導支持此舉。由於運動神經元流失具有不可逆性，必須及時進行藥物干預以優化患者預後，這凸顯了早期檢測的必要性。

The authorization of nusinersen and risdiplam, coupled with ongoing neonatal screening research, marks a shift toward standardized management of spinal muscular atrophy in England.

nusinersen 與 risdiplam 的獲准使用，加上持續進行的新生兒篩檢研究，標誌著英格蘭在脊髓性肌肉萎縮症的標準化管理方面取得了轉型。